Pittsburgh, PANCT07423078Now EnrollingIRB Ready

Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) Clinical Trial in Pittsburgh, PA

Access cutting-edge head and neck squamous cell carcinoma (hnscc) - recurrent/metastatic (r/m) treatment through this clinical trial at a research site in Pittsburgh. Study-provided care at no cost to qualified participants.

Sponsored by Matthew Spector

Quick Self-Assessment

See if you qualify for this Pittsburgh location

Preparing your pre-screening questions…

Expert Care in Pittsburgh

Access head and neck squamous cell carcinoma (hnscc) - recurrent/metastatic (r/m) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related head and neck squamous cell carcinoma (hnscc) - recurrent/metastatic (r/m) treatment provided free

Apply for This Pittsburgh Location

Check if you qualify for this head and neck squamous cell carcinoma (hnscc) - recurrent/metastatic (r/m) clinical trial in Pittsburgh, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Pittsburgh

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Pittsburgh site if eligible
  4. 4Begin participation

About This Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) Study in Pittsburgh

This trial will study the safety and tolerability and disease survival rates in adult patients with recurrent/metastatic (R/M) HNSCC when treated with carboplatin or cisplatin, paclitaxel, and toripalimab.

Sponsor: Matthew Spector

Who Can Participate

Inclusion Criteria

Pathologically confirmed and previously untreated squamous cell carcinoma of the larynx or hypopharynx
AJCC 8th Edition Stage III - IV disease (T1-T2/N1-N3, T3-T4/N0-N3)
Disease (primary \& nodal) must be potentially surgically resectable and curable with conventional surgery and CRT
ECOG PS 0 - 2
Sexually active fertile subjects and their partners must agree to use highly effective method of contraception prior to study entry, during the course of the study, and for 1 year after the last dose of treatment (whichever is later). An additional contraceptive method, such as a barrier method (e.g., condom), is required. In addition, men must agree not to donate sperm and women must agree not to donate eggs (ova, oocyte) for the purpose of reproduction during these same periods.
Female subjects of childbearing potential must not be pregnant or breastfeeding at screening. Female subjects are considered to be of childbearing potential unless one of the following criteria is met: Permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented postmenopausal status (defined as 12 months of amenorrhea in a woman \> 45 years-of-age in the absence of other biological or physiological causes). Note: Documentation may include review of medical records, medical examination, or medical history interview by study site staff.
Must have normal organ and marrow function as defined below:
Hemoglobin ≥ 9.0 g/dL
Absolute neutrophil count ≥ 1,500/mcL
Platelet count ≥ 100,000/mcL
Total bilirubin ≤ 1.5 X the institutional upper limit of normal (ULN)
AST (SGOT) ≤ 2.5 X institutional upper limit of normal (ULN)
ALT (SGPT) ≤ 2.5 X institutional ULN
Creatinine clearance ≥ 40 mL/min/1.73 m2 for patients with a creatinine level above institutional normal
Must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

Prior treatment for head and neck cancer
Unresectable laryngeal or hypopharyngeal squamous cell carcinoma
Distant metastatic disease
Has an active autoimmune disease requiring systemic treatment within the past 3 months, or a syndrome that requires ongoing systemic steroids or immunosuppressive agents. Subjects with vitiligo, Grave's disease, or psoriasis not requiring systemic therapy or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with hypothyroidism or Sjogren's syndrome will not be excluded from the study.
Has a history of non-infectious pneumonitis that required steroids, evidence of interstitial lung disease, or currently active non-infectious pneumonitis.
Known allergy or hypersensitivity to carboplatin or cisplatin, toripalimab, or paclitaxel.
Prior malignancy within 2 years that in the investigator's opinion would be likely to affect the outcomes for the patient.
Peripheral sensory neuropathy \> grade 2 by CTCAE v5.0
Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
Has acute or chronic active hepatitis B and C virus infection or known history of untreated hepatitis B (defined as hepatitis B surface antigen \[HBsAg\] reactive) or known active hepatitis C virus (HCV) (defined as HCV RNA \[qualitative\]) or HIV infection (see note).
Note: No testing for Hepatitis B, Hepatitis C, or HIV is required unless mandated by local health authority or clinically indicated.
Note: Participants with a history of HIV infection are considered eligible if CD4+ T cell counts are ≥350 cells/µL and the patient has had no opportunistic infections in the last 12 months.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Pittsburgh?

Yes, this clinical trial (NCT07423078) has an active research site in Pittsburgh, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) Treatment Options in Pittsburgh, PA

If you're searching for head and neck squamous cell carcinoma (hnscc) - recurrent/metastatic (r/m) treatment options in Pittsburgh, PA, this clinical trial (NCT07423078) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Pittsburgh research site is actively enrolling participants for this clinical trial. You'll receive care from experienced head and neck squamous cell carcinoma (hnscc) - recurrent/metastatic (r/m) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all head and neck squamous cell carcinoma (hnscc) - recurrent/metastatic (r/m) clinical trials near you to find additional studies recruiting in your area.

More Head and Neck Cancer Trials in Pittsburgh, PA

See all head and neck cancer clinical trials recruiting in Pittsburgh — not just this study.

Browse Head and Neck Cancer Trials in Pittsburgh →

Browse More Trials by Condition

Head and Neck Cancer TrialsAlzheimers Disease TrialsEssential Tremor TrialsAnkylosing Spondylitis TrialsAtopic Dermatitis TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Pittsburgh?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Pittsburgh, PA